Solventum Corporation SOLV SPXR3KPHARMA
Company Overview
Solventum Corporation, a healthcare company, develops, manufactures, and commercializes a portfolio of solutions to address critical customer and patient needs in the United States and internationally. It operates through three segments: Medsurg, Dental Solutions, and Health Information Systems. The Medsurg segment offers solutions, such as negative pressure wound therapy, advanced wound dressings, advanced skin care, synthetic tissue matrices, I.V. site management, sterilization assurance, temperature management, surgical supplies, medical tapes and wraps, stethoscopes, medical electrodes, and medical technologies for original equipment manufacturers. The Dental Solutions segment provides dental and orthodontic products, including brackets, aligners, restorative cements, and bonding agents to span the life of the tooth, and products for preventative dental care, direct and indirect restoration, and orthodontic needs. The Health Information Systems segment offers healthcare systems with software solutions comprising computer-assisted physician documentation, direct-to-bill and coding automation, classification methodologies, speech recognition, and data visualization platforms. The company sells its products and services through direct-to-consumer, distribution, key account management, inside sales, and e-commerce. Solventum Corporation was incorporated in 2023 and is headquartered in Eagan, Minnesota.
Why Investors Should Care
Generates a return on equity of 34.0%, reflecting efficient use of shareholder capital.
Return on capital employed stands at 19.6%.
Trades at a P/E of 11.2, below the sector median of 25.2.
Maintains a net profit margin of 17.3%.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $8.32B (+0.9% YoY); net profit $1.56B.
- Trailing 12 Months Year-on-year growth — revenue +2.2%, earnings +3.9%.
- 5-Year Trend Long-term compounding — revenue CAGR 0.8%, profit CAGR 5.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 0.79% |
| 1 Year: | 2.20% |
Compounded Profit Growth
| 5 Years: | 5.03% |
| 1 Year: | 3.90% |
Stock Price Performance
| 1 Year: | +23.27% |
| 6 Months: | +32.10% |
| 3 Months: | +13.18% |
| 1 Month: | +10.52% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)64.26 · Neutral
P/E of 11.21 is below the sector median of 25.17 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 34.0%.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | SOLV Solventum Corporation SPXR3KPHARMA | 91.69 | 11.21 | $15.61B | 0.00% | 19.55% | 33.96% | 0.79% | 5.03% |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.01B | 2.08B | 2.07B | 2.02B | 2.08B | 2.08B | 2.07B | 2.16B | 2.10B | 2.01B | 2.21B |
| Gross Profit | 1.14B | 1.19B | 1.21B | 1.17B | 1.14B | 1.17B | 1.11B | 1.18B | 1.14B | 1.10B | 1.29B |
| Operating Income | 365.00M | 417.00M | 504.00M | 381.00M | 244.00M | 275.00M | 152.00M | 214.00M | 1.69B | 81.00M | 181.00M |
| Net Income | 293.00M | 321.00M | 460.00M | 237.00M | 89.00M | 122.00M | 137.00M | 90.00M | 1.27B | 13.00M | 92.00M |
| Diluted EPS | 1.70 | 1.86 | 2.66 | 1.37 | 0.51 | 0.70 | 0.78 | 0.51 | 7.22 | 0.07 | 0.53 |
| R&D Expense | 195.00M | 193.00M | 180.00M | 195.00M | 192.00M | 189.00M | 193.00M | 189.00M | 183.00M | 189.00M | 178.00M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Revenue | 8.13B | 8.20B | 8.25B | 8.32B |
| Gross Profit | 4.70B | 4.69B | 4.59B | 4.45B |
| Operating Income | 1.69B | 1.69B | 1.04B | 2.18B |
| Net Income | 1.34B | 1.35B | 479.00M | 1.56B |
| Diluted EPS | 7.78 | 7.79 | 2.76 | 8.88 |
| R&D Expense | 767.00M | 758.00M | 775.00M | 739.00M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | - | 13.94B | 14.46B | 14.29B |
| Total Equity | 12.06B | 11.74B | 11.67B | 2.96B | 5.05B |
| Cash & Equivalents | - | - | 194.00M | 762.00M | 878.00M |
| Long Term Debt | - | - | 0 | 7.81B | 5.04B |
| Total Liabilities | - | - | 2.28B | 11.50B | 9.24B |
| Current Liabilities | - | - | 1.73B | 2.70B | 3.14B |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Operating Cash Flow | 1.68B | 1.92B | 1.19B | 369.00M |
| Investing Cash Flow | -253.00M | -230.00M | -380.00M | 2.80B |
| Financing Cash Flow | -1.46B | -1.55B | -240.00M | -3.06B |
| Capital Expenditure | -251.00M | -290.00M | -380.00M | -379.00M |
| Free Cash Flow | 1.43B | 1.62B | 805.00M | -10.00M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Gross Margin % | 57.7% | 57.3% | 55.6% | 53.5% |
| Operating Margin % | 20.8% | 20.6% | 12.6% | 26.2% |
| Net Margin % | 16.5% | 16.4% | 5.8% | 18.7% |
| ROE % | 11.4% | 11.5% | 16.2% | 30.8% |
| ROCE % | - | 13.9% | 8.8% | 19.5% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Independent Franchise Partners, LLP | 9.50% | 16.17M | $1.47B |
| 2 | Blackrock Inc. | 5.73% | 9.76M | $889.50M |
| 3 | Vanguard Capital Management LLC | 5.65% | 9.62M | $877.01M |
| 4 | Trian Fund Management, LP | 4.84% | 8.24M | $750.53M |
| 5 | Vanguard Portfolio Management LLC | 3.72% | 6.33M | $576.67M |
| 6 | Davis Selected Advisers | 3.71% | 6.31M | $574.76M |
| 7 | State Street Corporation | 3.31% | 5.64M | $513.85M |
| 8 | Geode Capital Management, LLC | 2.88% | 4.91M | $447.46M |
| 9 | Boston Partners | 2.37% | 4.04M | $367.94M |
| 10 | Invesco Ltd. | 1.94% | 3.31M | $301.60M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for SOLV
Solventum (SOLV) Up 11.4% Since Last Earnings Report: Can It Continue? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMilAFBVV95cUxPZjdLSzRzcGxpNXdmbmRSWU82MlpocHFBOXVKdmFSNnJ4TklRYW5RbTVSVVU2WVl3Z0wzUkhsVlp3V0wxbk0ydllJNHppNk9aUzJzTml0NHdwSUtJeGxKRGFVUnJPNjZ4aEtjdnpwcENEMTJWUDRKRlJWOEtxeHZTbVVwYXFsZ2pSU0doaE…
SOLV Energy: PV Enabler Looks A Lot Brighter Here (NASDAQ:MWH) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMikwFBVV95cUxQd2dabWlOWlJBZVZqVU04ZjFXVTd5bG1Jbm9rYy1McndUOW14TmU3YkpTU2ZrTTBTT3dDS1kwWTFXV1JYRmRBWFdlVENnYlcyNjNJY0s5Mk9YMF9hRGRXNkppbk5TS09jYTlwQnQwNE5KckFuTjk0elQwcDdzT2JpU3p5aXFVY0tFRU5aV0…
Is Solventum (SOLV) Fairly Valued On Raised 2026 Guidance Despite Debt And Cost Headwinds? - simplywall.st
<a href="https://news.google.com/rss/articles/CBMixwFBVV95cUxPMXdyY0piN3laR28zV19PZU9nTEZaYzhyMDhUTXdfMDdGMnJGdm9ZUHJSdHFodUpGYzBzOENIbERZaElxUUlMZ1RtT1RCakhEN2dWUGxYMUg4YnhidHRfenZzV1BFQlhyR19lZldqZ1UxUHRHSkpmcnBVSndMVGFCUzJYQkVEbWF2Q1RueV…
(SOLV) Risk Channels and Responsive Allocation - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxPbzNnNWNMY09zOG1UV240YW93WnRjOXVkZkxnWkhMNG1LRUdRWFc1MXowR2I4N3JmcGJmbTdVZURvVElVajcybnd0TVJUQmkzZHJiOVpYZi1wUVhwQ1IxUkg2M1RTUWVUZFlwUjQzTXZtWGFDak1mRVliVUwtNWdoOGEtbWd1bkZPOVpVRl…
SOLV Energy (MWH) Stock Could Be 49% Undervalued After Raised Guidance - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxOR2VkcklHYWZ1Ym16aW1oYmRZeFBkZGRVREI3ZlJNd0NUclVxZ3RvSVhtamtNUXBRbXBfTWhQbWtZSmt4Q3loZzdZbV83V3Nwb0V4T093RDNVbFBtRkpUTWFmQ2IxYUZPUDFkZmhKLXh1dmlBd1RpZHJKRGpWWFNxc1NISDNUOEt5MDFTNn…
Should Investors Buy SOLV as Growth Improves but Debt Risks Persist? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxQZnk0Q0dzVjBjVXNwRXVtZjB3NGNudTU5Ty1PV0dwcVF0TkJQbVMwT1dWekd0eUltY3R6YXRhMHNINHpWcWFnYlZsZ0R1Y1hsY19rZU0yREc0bHFnbldjaEhXcnJuX2ZrNm5SbFhDZjRBRzI0YkdGXzlNcHJrTWZBdFFJcWxsS1NhQnVFN1…
SOLV — Frequently Asked Questions
What is the current share price of Solventum Corporation (SOLV)?
As of 2026-09-07 16:24 PDT, Solventum Corporation (SOLV) trades at $91.69 on NYSE. Its 52-week range is $62.49 to $92.44.
What is the market capitalisation of SOLV?
Solventum Corporation (SOLV) has a market capitalisation of $15.61B on NYSE.
What is the P/E ratio of SOLV?
SOLV trades at a trailing price-to-earnings (P/E) ratio of 11.21. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 2.90.
What is the return on equity (ROE) of SOLV?
SOLV has a return on equity (ROE) of 33.96%. Its return on capital employed (ROCE) is 19.55%.
Is SOLV a good stock to buy?
This page provides a data-driven analysis of Solventum Corporation (SOLV), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.